Business Standard

Saturday, December 21, 2024 | 12:39 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Moderna says booster dose of its vaccine appears protective versus Omicron

The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year

moderna
Premium

Reuters
Moderna Inc said on Monday that a booster dose of its COVID-19 vaccine appeared to be protective against the fast-spreading Omicron variant in laboratory testing and that the current version of the vaccine would continue to be Moderna's "first line of defense against Omicron." The vaccine maker said the decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently discovered variant is spreading. The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year.

"What we have available right now

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in